- Acumen Powered by Robins Kaplan LLP™
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLPTM
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
October 19, 2021Three Robins Kaplan Partners Selected to Receive 2021 Minnesota Icon Award
-
October 18, 2021Women's Leadership Award Created in Memory of Hollis Salzman
-
October 13, 2021Robins Kaplan Files U.S. Supreme Court Amicus Brief on Behalf of Former National Security Advisors and Army Generals
-
October 25, 2021Women’s Bar Association of Massachusetts (WBA) 2021 Gala
-
October 28, 2021From Riches to Rags, a Story of a Damaged Nonprofit
-
October 29, 2021Eighth Circuit Judicial Conference
-
Fall 2021Are All Fiduciaries Created Equal?
-
Fall 2021Context Matters: Fiduciaries and the Rule Against Self-Dealing
-
Fall 2021Update on DOL Fiduciary Rule
-
October 19, 2021Financial Daily Dose 10.19.2021 | Top Story: SEC Issues Long-Awaited Report on Meme Stock Craze
-
October 18, 2021Financial Daily Dose 10.18.2021 | Top Story: Hollywood Crew Union Reaches Deal to Avert Strike; Shows to Go On
-
October 15, 2021Financial Daily Dose 10.15.2021 | Top Story: LinkedIn Shuts Down Site Access in China
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Generics Need Sword, Shield For 'Exceptional' Patent Case
Strategies for generic drug companies to avoid paying exceptional-case attorney fees and costs in patent litigation with brand holder.
September 18, 2014
Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.
All Content © 2003‐2014, Portfolio Media, Inc.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Jeffrey Alan Hovden
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.